Poloxamer 407-induced atherosclerosis in mice appears to be due to lipid derangements and not due to its direct effects on endothelial cells and macrophages

Mediators of Inflammation

Volumn 12, Issue 3, 2003, Pages 147-155

  Johnston, Thomas P ^a   Li, Yuai ^b   Jamal, Ahmed S ^a   Stechschulte, Daniel J ^b   Dileepan, Kottarappat N ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Inflammation; Interleukins; Lipid oxidation; Low density lipoprotein; Nitric oxide

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; POLOXAMER;

ANIMAL CELL; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CAUSE OF DEATH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; DISEASE MODEL; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIPID OXIDATION; MACROPHAGE FUNCTION; MALE; MOUSE; NONHUMAN; OXIDATION; PATHOGENESIS; PRIORITY JOURNAL; RABBIT; RAT; REGULATORY MECHANISM; SWINE; UMBILICAL VEIN; VASCULAR DISEASE;

ANIMALS; ARTERIOSCLEROSIS; CELL DIVISION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; LIPID METABOLISM; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; OXIDATION-REDUCTION; POLOXAMER; RATS; RATS, SPRAGUE-DAWLEY; SURFACE-ACTIVE AGENTS;

ANIMALIA; ORYCTOLAGUS CUNICULUS; SUS SCROFA;

EID: 0038442025     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/0962935031000134860     Document Type: Article

References (46)

1. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. J Am Med Assoc 1987; 257: 2176-2180.
2. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel in detection, evaluation, and treatment of high blood pressure in adults. Arch Intern Med 1988; 148: 36-69.
3. Jokinen M, Clarkson T, Prichard R. Animal models in atherosclerosis research. Exp Mol Patol 1985; 42: 1-28.
4. Van Lenten B. Animal models: the Watanabe heritable hyperlipidemic rabbit. In: Lusis A, Sparkes S, eds. Genetic Factors in Atherosclerosis: Approaches and Model Systems, Basel: Karger, 1989: 125-138.
5. Rapacz J, Hasler-Rapacz J. Animal models: the pig. In: Lusis A, Sparkes S, eds. Genetic Factors in Atherosclerosis: Approaches and Model Systems, Basel: Karger, 1989: 139-169.
6. Breslow JL. Mouse models of atherogenesis. Science 1996; 272: 685-688.
7. Paigen B, Plump AS, Rubin EM. The mouse as a model for human cardiovascular disease and hyperlipidemia. Curr Opin Lipidol 1994; 5: 258-264.
8. Wout Z, Pec EA, Johnston TP. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injections to rats. J Parent Sci Technol 1992; 46: 192-200.
9. Johnston TP, Palmer WK. Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochem Pharmacol 1993; 46: 1037-1042.
10. Li C, Palmer WK, Johnston TP. Disposition of poloxamer 407 following intraperitoneal injection to rats. J Pharm Biomed Anal 1996; 14: 659-665.
11. Johnston TP, Palmer WK. Effect of poloxamer 407 on the activity of microsomal 3-hydroxy-3-methylglutaryl CoA reductase in rats. J Cardiovasc Pharmacol 1997; 29: 580-585.
12. Palmer WK, Emeson EE, Johnston TP. The poloxamer 407-induced hyperlipidemic atherogenic animal model. Med Sci Sports Exer 1997; 29: 1416-1421.
13. Palmer WK, Emeson EE, Johnston TP. Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis 1998; 136: 115-123.
14. Johnston TP, Baker JC, Hall D, Jamal AS, Emeson EE, Palmer WK Potential downregulation of HMG-CoA reductase following chronic administration of P-407 to C57BL/6 mice. J Cardiovasc Pharmacol 1999; 34: 831-842.
15. Johnston TP, Baker JC, Hall D, Jamal AS, Emeson EE, Palmer WK. Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin. Atherosclerosis 2000; 149: 303-313.
16. Johnston TP, Coker JW, Paigen BJ, Tawfik OW. Sex does not seem to influence the formation of aortic lesions in the P-407-induced mouse model of hyperlipidemia and atherosclerosis. J Cardiovasc Pharmacol 2002; 39: 404-411.
17. Wasan KM, Subramanian R, Kwong M, Goldberg IJ, Wright T, Johnston TP. Poloxamer 407-mediated alterations in the activities of enzymes regulating cholesterol and triglyceride transport and metabolism in rats. J Pharm Pharmaceut Sci 2003; in press.
18. Johnston TP, Nguyen LB, Chu WA, Shefer S. Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis. Int J Pharm 2001; 229: 75-86.
19. Porter J, Carter B, Johnston TP, Palmer WK. Effect of pravastatin on poloxamer 407-induced hyperlipidemia in rats. Pharmacotherapy 1995; 15: 92-98.
20. Nash VJ, Johnston TP, Palmer WK. Effects of nicotinic acid on poloxamer 407-induced hyperlipidemia. Pharmacotherapy 1996; 16: 10-15.
21. Nash VJ. Effects of hypolipidemic drugs on poloxamer 407-induced hyperlipidemia. MS. Thesis. Chicago, IL: University of Illinois at Chicago, 1994: 1-164.
22. Li Y, Stechschulte AC, Smith DD, Lindsley HB, Stechschulte DJ, Dileepan KN. Mast cell granules potentiate endotoxin-induced interleukin-6 production by endothelial cells. J Leuk Biol 1997; 62: 210-216.
23. Li Y, Nguyen D, Stechschulte AC, Stechschulte DJ, Dileepan KN. Effect of mast cell granules on the gene expression of nitric oxide synthase and tumor necrosis factor-α in macrophages. Mediat Inflamm 1998; 7: 355-361.
24. Li Y, Chi L, Stechschulte DJ, Dileepan KN. Histamine-induced production of interleukin-6 and interleukin-8 by human coronary artery endothelial cells. Microvascular Res 2001; 61: 253-262.
25. Jehle AB, Li Y, Stechschulte AC, Stechschulte DJ, Dileepan KN. Endotoxin and mast cell granule proteases synergistically activate human coronary artery endothelial cells to generate interleukin-6 and interleukin-8. J Interferon Cytokine Res 2000; 20: 361-368.
26. Dileepan KN, Lorsbach RB, Stechschulte DJ. Mast cell granules inhibit macrophage-mediated lysis of mastocytoma cells (P815) and nitric oxide production. J Leuk Biol 1993; 53: 446-453.
27. Schmedes A, Hølmer G. A new thiobarbituric acid (TBA) method for determining free malondialdehyde (MDA) and hydroperoxides selectively as a measure of lipid peroxidation. J Am Oil Chem Soc 1989; 66: 813-817.
28. Snedecor GW, Cochran WG. Tests of hypotheses. In: Snedecor GW, Cochran GW, eds. Statistical Methods, Ames, IA: Iowa State University Press, 1980: 64-82.
29. Wang P, Johnston TP. Sustained release interleukin-2 following intramuscular injection in rats. Int J Pharm 1995; 113: 73-81.
30. Johnston TP, Punjabi MA, Froelich CJ. Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice. Pharm Res 1992; 9: 421-430.
31. Johnston TP, Miller SC. Toxicological evaluation of poloxamers for intramuscular use. J Parenter Sci Technol 1985; 39: 83-88.
32. Atkinson TP, Bullock JO, Smith TF, Mullins RE, Hunter RL. Ion transport mediated by copolymers composed of polyoxyethylene and polyoxypropylene. Am J Physiol 1988; 254: C20-C26.
33. Pec EA, Wout ZG, Johnston TP. Biological activity of urease formulated in poloxamer 407 following intraperitoneat injection in the rat. J Pharm Sci 1992; 81: 626-630.
34. Muller RH. Toxicity studies in hepatocyte cultures. In: Muller RH, ed. Colloidal Carriers for Controlled Drug Delivery and Targeting, Boca Raton, FL: CRC Press, 1991: 207-210.
35. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993; 54: 1-78.
36. Aarden L, Helle M, Boeije L, Pascual-Salcedo D, de Groot E. Differential induction of interleukin-6 production in monocytes, endothelial cells, and smooth muscle cells. Eur Cytokine Net 1991; 2: 115-120.
37. Gimbrone Jr M, Obin MS, Brock AF, et al. Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions. Science 1989; 246: 1601-1603.
38. Baggiolini M, Dewald B, Moser B Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1993; 55: 97-179.
39. Wang JM, Sica A, Peri G, et al. Expression of moncyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb 1991; 11: 1166-1174.
40. Brown Z, Gerritsen ME, Carley WW, Strieter RM, Kunkel SL, Westwick J. Chemokine gene expression and secretion by cytokine-activated human microvascular endothelial cells. Am J Pathol 1994; 145: 913-921.
41. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996; 127: 263-271.
42. Terkeltaub R, Banka CL, Solan J, Santoro D, Brand K, Curtiss LK. Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler Thromb 1994; 14: 47-53.
43. Patel RP, Levonen AL, Crawford JH, Darley-Usmar VM. Mechanisms of the pro- and anti-oxidant actions of nitric oxide in atherosclerosis. Atherosclerosis 2000; 47: 465-474.
44. Violi F, Marino R, Milite MT, Loffredo L. Nitric oxide and its role in lipid peroxidation. Diabetes Metab Res Rev 1999; 15: 283-288.
45. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density-lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.
46. Witztum JL, Steinberg D. Role of oxidized low-density-lipoprotein in atherogenesis. J Clin Invest 1992; 90: 1138-1144.